Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy

Heart

Volumn 95, Issue 9, 2009, Pages 709-714

  Lin, G ^a   Nishimura, R A ^a   Gersh, B J ^a   Phil, D ^a   Ommen, S R ^a   Ackerman, M J ^a   Brady, P A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; DEVICE INFECTION; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PERICARDIAL EFFUSION; PNEUMOTHORAX; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINUS TACHYCARDIA; SURVIVAL RATE; ADOLESCENT; AGE; CLINICAL COMPETENCE; EQUIPMENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATIENT SELECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUDDEN DEATH;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; CLINICAL COMPETENCE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT FAILURE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 65549134228     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.150656     Document Type: Article

References (23)

1. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687-713.
2. Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. New Engl J Med 2004; 350:1320-7.
3. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. JAmCollCardiol 2000; 36:2212-18.
4. Maron BJ, Spirito P, Shen W-K, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298:405-12.
5. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1-62.
6. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517-24.
7. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: A discussion of nomenclature. Am J Cardiol 1979; 43:1242-4.
8. McKenna WJ. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93:841-2.
9. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study. J Am Coll Cardiol 1983; 2:437-44.
10. Kiviniemi M, Pirnes MA, Eranen JK, et al. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 1999; 22:711-20.
11. Ellenbogen KA, Wood MA, Shepard RK. Delayed complications following permanent pacemaker implantation. Pacing Clin Electrophysiol 2002; 25:1155-8.
12. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007; 93:1044-5.
13. Begley D, Mohiddin S, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26:1887-96.
14. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28:334-14.
15. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter- defibrillator in patients with Brugada Syndrome: a multicenter study. Circulation 2006; 114:2317-24.
16. Theuns DAMJ, Klootwijk APJ, Goedhart DM, et al. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004; 44:2362-7.
17. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single- chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation 2006; 113:2871-9.
18. Bunch TJ, Munger TM, Friedman PA, et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 10:1009-14.
19. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28:2583-8.
20. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005; 111:2033-41.
21. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? JAMA 2007; 298:452-1.
22. Grace AA, Brady PA, Shapiro LM. Risk management in hypertrophic cardiomyopathy. The Lancet 2001; 357:407-8.
23. Saumarez RC, Pytkowski M, Sterlinski M, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008; 29:1653-61.